Stimulant withdrawal (cocaine/amphetamine) — behavioural
Stimulant withdrawal · Psychiatry / Behavioural
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Withdrawal from cocaine or amphetamines (the 'crash') produces dysphoria, intense fatigue, hypersomnia, increased appetite, agitation and — importantly — depression with a significant suicide risk, rather than the autonomic instability of alcohol/opioid withdrawal. Management is largely supportive with attention to mood and safety.
Red flags
- Suicidal ideation or plan (high risk during the crash)
- Psychotic symptoms persisting (consider stimulant-induced or primary psychosis)
- Chest pain or arrhythmia from recent use
- Severe depression or inability to self-care
- Evidence of rhabdomyolysis/AKI from prior agitation
Assessment
Differential diagnosis
- Stimulant withdrawal / crash (dysphoria, hypersomnia, craving)
- Major depressive episode (may be unmasked or precipitated)
- Ongoing intoxication or mixed-drug use
- Organic cause of low mood/fatigue (hypothyroidism, anaemia, infection)
- Alcohol or sedative withdrawal (different features)
Investigations
- Risk assessment for suicide (key — depression and craving peak in withdrawal)
- Capillary glucose and observations
- Toxicology and alcohol level
- Bloods: FBC, U&E, LFTs, CK (if recent agitation/rhabdomyolysis), TFTs
- ECG if recent stimulant use (ischaemia/arrhythmia)
Management
- Confirm withdrawal rather than intoxication or another cause
- Provide a calm, supportive environment with rest and hydration
- Assess and manage suicide risk carefully — this is the main danger in stimulant withdrawal
- Treat agitation or insomnia symptomatically if needed
- Screen for and manage complications of prior use (cardiac, rhabdomyolysis)
- Treat coexisting depression/psychiatric comorbidity with psychiatric input
- Refer to substance-misuse services and provide harm-reduction advice
- Arrange mental-health follow-up given relapse and suicide risk
Drugs & doses
No specific pharmacotherapy for stimulant withdrawal — supportive care is mainstay
Lorazepam — 1-2 mg PO for severe agitation/insomnia, short-term; max 4 mg/24h caution
Diazepam — 5-10 mg PO as an alternative for agitation
Antidepressants not started in ED — refer for assessment if depression persists
Disposition
Discharge most patients with substance-misuse referral and mental-health follow-up once suicide risk is assessed as low; admit or arrange urgent psychiatric review (MHA if needed) for high suicide risk or persisting psychosis.
Complications & pitfalls
- Suicide during the depressive crash
- Relapse to use
- Prolonged depression and anhedonia
- Cardiac sequelae of prior stimulant use
- Social and functional decline
Exam pearls
- The danger in stimulant withdrawal is depression and suicide, not autonomic collapse — prioritise risk assessment
- There is no proven specific pharmacotherapy; treatment is supportive with mood/suicide focus
- Craving and low mood peak early and then improve over days to a week
- Persisting psychosis after the crash suggests a stimulant-induced or primary psychotic disorder
- Use the presentation to engage the patient with substance-misuse and mental-health services
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.